Oric Pharmaceuticals将公布Rinzimetostat治疗MCRPC患者1B期试验联合剂量优化数据

美股速递
Mar 27

Oric Pharmaceuticals Inc. 即将公布其药物Rinzimetostat在转移性去势抵抗性前列腺癌(MCRPC)患者中开展的1B期临床试验的联合剂量优化数据。该数据旨在评估Rinzimetostat与其他药物联合使用时的最佳剂量方案,为后续临床开发提供关键依据。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10